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Digital devices play an important role in medical treatment and 
will in the future play a larger role in connection to cures of 
health-related issues.  
Traditionally medicine has been tested by clinical double blind, 
randomized trials to document the eﬃcacy and safety proﬁle. 
When it comes to the use of digital devices in treatments the 
protocols from the ﬁeld of medicine is adopted. The question is 
whether or not this evidence based approach is useful when 
dealing with digital devices and whether the understanding of 
the eﬃciency of a treatment can be obtained without also 
looking at usability and lifestyle issues. 
Based on a case study of epilepsy, a literature study of protocols 
for investigating treatments using digital medical devices, the 
set-up of studies, the design of a current protocol for clinical 
trials, and ﬁnally preliminary results, we discuss if clinical trials 
have to include usability studies to determine if a treatment is 
eﬀective.* 
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1 INTRODUCTION 
In recent years the number of websites and apps for self-
monitoring of health issues from sports performance to tobacco 
addiction has exploded, apps have been developed for e.g. self-
monitoring of illnesses like diabetes, asthma, and bipolar 
disorder. Following this development, there is an increased 
interest in researching whether or not the digital systems 
support health. Examples include behavior change that helps 
people quit smoking or lose weight, mental health applications 
that e.g. address depression or anxieties, management of chronic 
diseases using the Internet and app-based management systems 
e.g. self-management of diabetes [11] and bipolar disorder [1]. 
Other examples include patient-accessible personal health 
records and tailored educational programs for patients [6]. Other 
technologies support compliance through behavioral changes 
with different intervention strategies  [12].  
The number of electronic devices within the area of health 
are increasing such as an electronic device for the treatment of 
headaches for migraine patients [20]. A variation of these are 
devices that uses electric stimulation on a specific nerve or 
organ. Most are implants with little or no user interaction, but an 
increasing number stimulates a nerve on the outer body with a 
demand for user interactions such as the digital device for 
lowering the number of epileptic attacks for patients with drug-
resistant epilepsy, presented later in this paper. Eysenbach et. al. 
[6] has developed a standard for reporting of randomized 
controlled trials within eHealth and mHealth trials to provide a 
broad guidance. The standard includes descriptions of who is 
involved, the technology, the usage, and the usability test 
methods. The standard is heavily cited (1014 on Journal of 
Medical Internet Research (JMIR), 521 on Google Scholar 
(August. 3, 2017) and has influenced many studies. The standard 
does include reports on usability tests in the design phase but 
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does not contain usability issues during the clinical research 
study.  
HCI studies on medical devices typically concern design 
issues, [1], [3], health management, and coordination issues, [5], 
[15], [4] Also, long-term studies of behavioral change in order to 
determine the effectiveness of these technologies are 
reported.   Klasjna, et.al. [12] argues for a narrower notion of 
efficacy, one that tailors outcome measures to the particular 
intervention strategies a technology employs. They suggest the 
construction of a value chain that evaluates the initial, 
intermediate and distal effects of the technology. This enables 
HCI researchers to test whether their systems work as intended 
right from the early stages of development.  
Within HCI there are good arguments for doing prototyping 
and studying early and later use and a large number of literature 
reports on the design process. But this is not well aligned with 
the mind-set that medical studies require where the effect of the 
medical treatment has to be studied in double-blind studies 
adapting methods from test of drugs in various form. To prove 
that a technology can reduce attacks or cure an illness other 
standard has to be applied, such as the drug review process 
developed by the American Food and Drug Administration 
(FDA), recognized worldwide as “the gold standard”. Thus, when 
it comes to proving whether or not an app or a device can reduce 
attacks, heighten compliance, or cure an illness evidence based 
research from the medical field is introduced. This paper 
deviates from much of the HCI literature in the medical field as 
it reports from a study that takes point of departure in evidence-
based medicine and the development of a protocol for clinical 
trials is the focus of this paper. 
2 EVIDENCE BASED MEDICINE  
The fundamental idea of evidence-based medicine is that not all 
evidence is created equal – some forms of evidence is deemed 
stronger than others. When one wants evidence for the efficacy 
of a (new) treatment the advised method is to conduct a double 
blind randomized controlled trial, this is referred to as the ‘gold 
standard'. Briefly told, the “gold standard” involves randomly 
dividing the patients taking part in the trial into two groups. One 
group of patients is given the active substance under 
examination, e.g. a drug, and the other group, designated the 
control group, is given a placebo (sham) treatment designed to 
have no effect [10]. 
In medical research, the concept of sham refers to introducing 
placebo medication for a randomized anonymous test-group. To 
replicate this protocol for clinical trials in the field of digital 
devices, some researchers have developed sham devices or used 
sham data [14] for randomized anonymous test-groups. One 
example of a sham device is a study of acupuncture versus 
diazepam in the treatment of pain. In this study, the sham 
acupuncture introduced real needles at sham acupuncture points 
[21]. Another sham intervention studied the antiepileptic effect 
of vagus nerve stimulation using a sham stimulation at the non-
vagus nerve innervated earlobe [13]. These sham set-ups have 
proven problematic; using sham needles and sham acupunctures 
pressure points might have an impact on the body [10], using a 
sham earlobe stimulation might affect the patients that can 
easily find information that the stimulation point is wrong. 
Some studies use sham data in connection with testing of 
eHealth within self-monitoring e.g. [14] these studies focus on 
usability rather than on actual proof of medication. Other studies 
create a baseline and compare compliance before, and after 
introducing a digital stimulation e.g. [20] use a digital device 
stimulation of the vagus nerve to reduce head ache of chronic 
migraine patients. Despite the use of a digital device, there is no 
inclusion of usability issues affecting the utilization. 
3 THE CASE 
Drug resistant epilepsy is a serious condition that often leads to 
a major impact on quality of life and poses significant life 
challenges due to the risk of depression, underemployment, 
injuries, and death. Despite the critical need, current treatments 
for this condition are far from satisfactory.  
Therapeutic electric brain stimulation techniques provide an 
option for treating drug resistant epilepsy. The devices act by a 
variety of mechanisms to decrease neuronal excitability probably 
by indirect modulation of cortical activity [7], [9]. One method is 
to stimulate the auricular branch of the vagus nerve in the 
human ear, so called transcutaneous vagus nerve stimulation (t-
VNS) [16]. Studies support the evidence of the efficacy of 
stimulating the vagus nerve in the ear; including a small clinical 
and experimental study [19], a subsequent multicenter 
randomized controlled double blind study based on 70 patients 
[2]. A Chinese study also found positive results [17]. Side effects 
were reported including dizziness, headache, local pain, 
dysaesthesia, and itch at the stimulation site. The side effects 
seem to be rapidly reversible and disappear soon after the 
stimulation is terminated. All studies, however, are relatively 
small and too underpowered to obtain statistically significant 
results. Based on the above there is a need for a clinical study 
that can determine if the electric stimulation of the vagus nerve 
in the outer ear can reduce the number of seizures.  
In the reported case, the first attempt to create a protocol 
involved a sham device and two randomly selected control 
groups. The rationale for the sham was adopted from the studies 
on in-operated stimulators [17] [10] [13] [8]. The first ideas to 
create a sham device involved having it emit a sound or 
vibration rather than an electrical current, and in that manner, 
create the illusion of the real device. This had to be abandoned 
because we found that the patients might readily notice the 
difference between electrical current and other forms of 
stimulation such as e.g. vibration or sound if we attempted this 
approach to making a sham device. The second idea was to not 
make a sham device as such but to have the device emit a 
different voltage as sham. We also had to abandon this idea 
because any voltage might be effective in ways not fully 
understood and hence not a true placebo. The third and final 
idea was to give the correct current, but at the wrong place on 
the ear i.e. place the electrode incorrectly. This also had to be 
abandoned due to the availability of instruction manuals online 
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– i.e. a patient seeking information could easily unmask the 
sham. For these reasons, we had to abandon the whole idea of 
basing our clinical trial on sham in any form. This echoes the 
sham trouble describe in the case of acupuncture [21]. 
Due to the difficulties in establishing a valid sham procedure, 
as we have seen, we have formulated an alternative within the 
framework of evidence-based medicine. 
 
Figure 1: The T-VNS device Nemos with the electrode to be 
placed at the outer ear. The device is the size of a cell 
phone. The patient interacts with the device to adjust 
amount of electricity and to follow compliance. 
4 DEVELOPING A PROTOCOL FOR A CLINICAL 
TRIAL INCLUDING DATA ON LIFESTYLE AND 
USABILITY ISSUES 
The idea is to pragmatically provide the best available evidence 
for the efficacy of t-VNS by indirectly evaluating whether 
patients continue to use the device after 6 months (end of study) 
and subsequently after 12 months follow up. Or if they quit use. 
We hypothesize that if the patient continues t-VNS they most 
likely experience significant clinical benefits. On the other hand, 
if the patient discontinues t-VNS it may be due to lack of effect, 
adverse effects, difficulty in functional handling of the device, or 
a lack of fit with the lifestyle of the patient. 
It is in determining why the patients discontinue the 
treatment that the need for data on usability and lifestyle issues 
becomes apparent. It is (partly) through this data generated 
through questionnaires and interviews that we will be able to 
determine the root of the reasons for the patients abandoning 
the t-VNS treatment. Is it because of a lack of effect of the 
electrical stimulation treatment? Is it because the device is not 
user-friendly? Is it because the treatment has a bad fit with the 
lifestyle of the patient (e.g. the patient cannot find the time to 
use the device for 4 hours every day)? Or is it a combination of 
these issues? Due to the design of the clinical trial where 
Informatics and HCI components are included, we are in fact 
able to answer these questions (both statistically and 
qualitatively).  
To be clear, in this context of a clinical trial, the data on the 
usability and lifestyle issues are not there for design use. They 
are only there to be able to be taken into consideration when the 
evidence of the efficacy of the treatment is to be established. 
That there is a large potential for this data to be used in a device 
re-design process is of course beneficial, but of secondary 
importance in this context of evidence-based medicine.  Having 
said that, we are of course interested in redesigning the device in 
collaboration with its manufacturer in order to ensure a better 
delivery of the active component, namely, the electrical 
stimulation. But to spell it out, the contribution of Informatics 
and HCI to evidence-based medicine, to clinical trials, can be 
described as being a provider of data, to be used in calculating 
trial outcome, rather than a design contribution. The design 
contribution is an afterthought - an important one - but seen 
from the perspective of evidence-based medicine nonetheless an 
afterthought.  
The following quotes from two patients illustrate the 
problems of usability and lifestyle issues: 
Participant 1: "It was in the afternoon/evenings I used it. I didn't 
get it as evenly distributed, as I should. I didn't use it four times for 
one hour. Most often it was, as you say, afternoon and evenings. 
Rather one time of two hours and then maybe one hour during the 
working day. Sometimes longer periods of one and a half hour at 
afternoons and evenings, because it is easy to wear when you 
watch television and sit quietly at home." (Translated from Danish 
by authors.) 
Participant 2: I use it when I come home from work because I 
find it highly annoying that you have to clean it all the time. I 
have sometimes wanted to through the device out of the window 
(laughs). Because you have to clean your ear all the time 
Interviewer: Ah yes, there is this contact fluid? Do you have to rinse 
the ear to create contact? 
Participant 2: If it is away from the ear then you have to rinse 
again - both the ear and this thingy.” (Translated from Danish by 
authors.) 
Participant 1: "The problem is if you have a job where you sit 
down it is no problem. You just have to explain to people around 
you what it is. If you have a …, I'm a xx, and walks around, or if 
you have to do something where you have to move, then it is a bit 
difficult." (Translated from Danish by authors.) 
As can be seen from the quotes the difficulties arise from the 
device - the electrodes easily fall off and the circumstance that 
you have to clean the ear every time the electrodes fall off.  The 
difficulties also originate from a social context where the patient 
has to answer questions about the device and electrodes from the 
surroundings.   
We may say, then, that there is reason to think that lifestyle 
and usability issues will impact the outcome of the trial and data 
needs to be collected on these issues in a systematic manner, in 
order to have a valid clinical trial of the medical t-vns device. As 
indicated, it may not only be because of the electrical stimulation 
being ineffective that some patients may quit treatment.  
 




From our case, we argue that when it comes to digital devices 
“the gold standard” is not enough. HCI needs to be considered 
when medical devices are clinically tested. Researching the use 
situations,  we can get inspiration from studies that look at 
proximal effects; intermediate effects, and distal effects that are 
evaluated through multiyear longitudinal research [18]. We can 
create transparency in the design and test phases as suggested 
by [3]. But how can we significantly know to what degree the 
patient population may be said to quit because of experiencing a 
lack of efficacy? A lack of fit with their lifestyles? Or an inability 
to functionally use the device?  
Generating data on all of these fronts will, first, provide an 
empirical basis for evaluating the effect of the device, and 
second, it will provide a basis for a redesign of the device if the 
data shows a need for it.  
If one fails to generate data on usability and lifestyle issues, 
for example, the trial design may be biased towards explaining a 
lack of success with the patient population purely in terms of the 
efficacy of the active components of the treatment. This may be 
incorrect, and a may lead investigators to miss an opportunity, 
for example for a simple redesign of the device, which may in 
some cases potentially lead to an increased uptake in compliance 
with what is otherwise treatment with good efficacy.    
Similarly, to [12] we propose that HCI researchers should use 
qualitative studies that focus on people’s experiences with the 
technology in order to understand why and how the system is 
working and participate in randomized control trials. The 
question becomes: How can HCI researchers approach the 
medical field and be accepted into the clinical trials? 
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